Trials / Completed
CompletedNCT03482713
Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)
Phase II Study, Randomized, Double-Blind, Placebo-Controlled 4-Week Clinical Study, to Evaluate the Efficacy and Safety of MK-7264 in Adult Japanese Participants With Unexplained or Refractory Chronic Cough
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This estimation study (no hypotheses) will evaluate the safety, tolerability, and efficacy of gefapixant (MK-7264) in Japanese adult participants with unexplained or refractory chronic cough.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefapixant 45 mg | Gefapixant 45 mg (film-coated tablet) to be administered orally BID |
| DRUG | Placebo | Placebo (film-coated tablet) matching gefapixant to be administered orally BID |
Timeline
- Start date
- 2018-03-16
- Primary completion
- 2018-06-07
- Completion
- 2018-06-07
- First posted
- 2018-03-29
- Last updated
- 2019-10-17
- Results posted
- 2019-07-05
Locations
16 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03482713. Inclusion in this directory is not an endorsement.